Health TrialsbyHealthPanel

An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

ConditionGeographic Atrophy
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age50+
SponsorAnnexon, Inc.

About this trial

The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.

Disqualifiers

Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.

Trial design

Design model

Single group

Treatments tested in this trial

  • Vonaprument

    Drug

    Form: solution for injection; Route of Administration: IVT injection

Treatment groups

605 Participants
are divided into 1 treatment group
Group A: VonaprumentExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Number of Participants with Treatment Emergent Adverse Events

Time frame
Through Month 24

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Annexon, Inc.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: